Calyxo Closes on $50 Million Equity Financing to Support Broad Launch of CVAC Kidney Stone Treatment
Summary
Calyxo Closes on $50 Million Equity Financing to Support Broad Launch of CVAC Kidney Stone TreatmentInvestment Round will Fund Expansion of Commercial Team and Further Product DevelopmentPLEASANTON, Calif., December 12, 2023-- Calyxo, Inc., a medical device company developing next-generation treatment solutions for patients with kidney stones, has announced the closing of a $50 million Series D financing round led by Avidity Partners with significant participation from existing investors Questa Capital and CRG. The Firm uses its industry backgrounds along with scientific and capital markets expertise to provide flexible financing options designed to help entrepreneurs and companies pursue promising solutions for unmet medical needs. The firm seeks to invest between $20 - $300 million in companies across the healthcare spectrum, including: medical devices, biopharmaceuticals, tools & diagnostics, services and information technology. CRG provides growth capital in the form of long-term debt and equity to support innovative, commercial-stage healthcare companies that address large, unmet medical needs. The firm partners with public and private companies to provide flexible financing solutions and world-class support to achieve exceptional growth objectives with minimal dilution.